Literature DB >> 12660512

Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study.

Luciano Potena1, Francesco Grigioni, Paolo Ortolani, Gaia Magnani, Cinzia Marrozzini, Elena Falchetti, Alessandra Barbieri, Letizia Bacchi-Reggiani, Tiziana Lazzarotto, Antonio Marzocchi, Carlo Magelli, Maria P Landini, Angelo Branzi.   

Abstract

BACKGROUND: Transplant coronary artery disease (TxCAD) is a major cause of long-term mortality after heart transplantation. Although vascular remodeling has been implicated in the pathophysiology of TxCAD, its determinants remain unknown.
METHODS: Twenty-nine consecutive heart-transplant recipients prospectively received intravascular ultrasound (IVUS) of the left-anterior descending artery 1 and 12 months after transplant, with volumetric reconstruction of the proximal 30 mm.
RESULTS: Overall, patients exhibited intimal volume increase (+83%, P<0.001), wheras vessel volume remained largely unchanged (+4%, P=0.270); consequently, overall lumen volume decreased (-6%, P=0.058). Among the clinical and laboratory variables, cytomegalovirus (CMV) infection requiring treatment (occurring in 12 patients), as assessed by pp65 antigenemia, was independently associated with the impaired ability of the vessel wall to enlarge in response to intimal volume increase, ultimately resulting in lumen loss (OR [95% CI]=0.098 [0.010-0.920]; P=0.042). However, adequate vessel response to intimal hyperplasia with consequent lumen preservation was observed in the remaining 17 patients who did not present CMV infection requiring treatment.
CONCLUSIONS: The present study demonstrates that either adequate or inadequate coronary remodeling may occur during the first year after transplantation. Moreover, for the first time, it strongly suggests that remodeling modalities may be negatively influenced by the occurrence of clinically relevant CMV infection. Randomized prospective trials are warranted to investigate whether aggressive treatment of CMV infection may help prevent TxCAD.

Entities:  

Mesh:

Year:  2003        PMID: 12660512     DOI: 10.1097/01.TP.0000054231.42217.A5

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  A20-mediated modulation of inflammatory and immune responses in aortic allografts and development of transplant arteriosclerosis.

Authors:  Jeffrey J Siracuse; Mark D Fisher; Cleide G da Silva; Clayton R Peterson; Eva Csizmadia; Herwig P Moll; Scott M Damrauer; Peter Studer; Lynn Y Choi; Sanah Essayagh; Elzbieta Kaczmarek; Elizabeth R Maccariello; Andy Lee; Soizic Daniel; Christiane Ferran
Journal:  Transplantation       Date:  2012-02-27       Impact factor: 4.939

2.  Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection.

Authors:  Davide Abate; Marta Fiscon; Alda Saldan; Simona Cofano; Carlo Mengoli; Dino Sgarabotto; Chiara d'Agostino; Luisa Barzon; Riccardo Cusinato; Giuseppe Toscano; Giuseppe Feltrin; Antonio Gambino; Gino Gerosa; Giorgio Palù
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

Review 3.  Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets.

Authors:  Luciano Potena; Hannah A Valantine
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 4.  Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation.

Authors:  Amandeep Dhaliwal; Vinay Thohan
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

5.  Evolving concepts and treatment strategies for cardiac allograft vasculopathy.

Authors:  Rodolfo Denadai Benatti; David O Taylor
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-01

Review 6.  Endothelial dysfunction and cardiac allograft vasculopathy.

Authors:  Monica Colvin-Adams; Nonyelum Harcourt; Daniel Duprez
Journal:  J Cardiovasc Transl Res       Date:  2012-11-08       Impact factor: 4.132

7.  RCMV increases intimal hyperplasia by inducing inflammation, MCP-1 expression and recruitment of adventitial cells to intima.

Authors:  Cecilia Söderberg-Nauclér; Piotr Religa; Monika K Grudzinska; Krzysztof Bojakowski; Joanna Soin; Frank Stassen
Journal:  Herpesviridae       Date:  2010-12-23

Review 8.  Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.

Authors:  Federico Rea; Luciano Potena; Nizar Yonan; Florian Wagner; Fiorella Calabrese
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

9.  Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.

Authors:  Inger Johansson; Rune Andersson; Vanda Friman; Nedim Selimovic; Lars Hanzen; Salmir Nasic; Ulla Nyström; Vilborg Sigurdardottir
Journal:  BMC Infect Dis       Date:  2015-12-24       Impact factor: 3.090

Review 10.  Cytomegalovirus infection in immunosuppressed patients after kidney transplantation.

Authors:  Simona Luscalov; Luminita Loga; Lucia Dican; Lia Monica Junie
Journal:  Clujul Med       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.